Gemer DS 3 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 3mg and Metformin 1000mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, functions by stimulating pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, enhancing glucose uptake and utilization. The synergistic effect of these two agents helps achieve better glycemic control in patients inadequately managed by diet, exercise, or monotherapy. Gemer DS 3 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and hypoglycemia, particularly due to Glimepiride. Regular monitoring of blood glucose levels, renal function, and periodic assessment of liver enzymes is recommended during therapy. Dose adjustments may be necessary based on therapeutic response and tolerability. This combination therapy should be used under medical supervision to optimize efficacy and minimize risks.